Stock AGEN AGENUS INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Agenus Inc.

Equities

AGEN

US00847G8042

Real-time Estimate Cboe BZX
Other stock markets
 01:00:28 2024-05-10 pm EDT 		5-day change 1st Jan Change
10.52 USD -10.20% Intraday chart for Agenus Inc. -19.59% -36.53%
May. 07 Sector Update: Health Care Stocks Stronger in Tuesday Afternoon Trading MT
May. 07 Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Sector Update: Health Care Stocks Stronger in Tuesday Afternoon Trading
MT
Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates
MT
Transcript : Agenus Inc., Q1 2024 Earnings Call, May 07, 2024
Earnings Flash (AGEN) AGENUS Reports Q1 Revenue $28M
MT
Agenus: Q1 Earnings Snapshot
AQ
Agenus Reports First Quarter 2024 Results
BU
Agenus Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Ligand and Agenus Enter into $100 Million Royalty Financing Agreement to Support Agenus? Key Development Initiatives in the Ongoing Bot/Bal Clinical Development Program
CI
Agenus Regains Compliance with Nasdaq Minimum Bid Price Requirement
BU
Agenus Inc. - Botensilimab, Balstilimab Data in MSS CRC Selected for the American Society of Clinical Oncology 2024 Annual Meeting
AQ
Botensilimab/Balstilimab Data in MSS CRC Selected for the American Society of Clinical Oncology 2024 Annual Meeting
BU
Agenus to Provide First Quarter 2024 Financial Report and Corporate Update
BU
Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer
AQ
Sector Update: Health Care Stocks Slipping Late Afternoon
MT
Sector Update: Health Care
MT
Agenus Shares Decline After Update on Early Stage Colorectal Cancer Drug Trial
MT
Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer
BU
Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer
CI
Reverse Split: 1 of 20
FA
Agenus Stockholders Approve 1-for-20 Reverse Stock Split
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AGEN Stock
  4. News Agenus Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW